Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00333593




Registration number
NCT00333593
Ethics application status
Date submitted
5/06/2006
Date registered
6/06/2006
Date last updated
27/12/2006

Titles & IDs
Public title
Super High-Flux - High Volume Dialysis in Sepsis-Induced Acute Renal Failure
Scientific title
Randomized, Cross Over Study Comparing Standard Hemodialysis to Hemodialysis With a Novel Polyamide Membrane (P2SH) in Patients With Sepsis and Acute Renal Failure
Secondary ID [1] 0 0
H2003/01440
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Sepsis 0 0
Acute Renal Failure 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Injuries and Accidents 0 0 0 0
Poisoning
Blood 0 0 0 0
Other blood disorders
Infection 0 0 0 0
Other infectious diseases
Renal and Urogenital 0 0 0 0
Kidney disease
Injuries and Accidents 0 0 0 0
Other injuries and accidents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Large pore dialyser
Treatment: Devices - Standard dialyser

Treatment: Devices: Large pore dialyser


Treatment: Devices: Standard dialyser
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The primary outcome measure for this study is the relative change in plasma IL-6 levels.
Timepoint [1] 0 0
Secondary outcome [1] 0 0
The secondary outcome is the clearance and the absolute change in the levels of IL-6 and other cytokines.
Timepoint [1] 0 0
Secondary outcome [2] 0 0
The other secondary outcome is the change in noradrenaline dose required to maintain baseline mean blood pressure (typically 70 mmHg)
Timepoint [2] 0 0
Secondary outcome [3] 0 0
change in the levels of other cytokines.
Timepoint [3] 0 0

Eligibility
Key inclusion criteria
- All patients who fulfil the consensus criteria for sepsis (21) and recently proposed
criteria for severe ARF (1) are eligible for the study.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients under 18 years of age.

- Patients who are pregnant or breastfeeding

- Patients with a known allergy to polyamide

- Patients expected to die within 24 hours

- Patients in whom there are limitations on the intensity of therapy

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Austin Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
3084 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
Austin Health
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Patients within the intensive care unit who have severe infections causing shock and kidney
failure have almost a 60% risk of dying despite antibiotic therapy, surgical drainage of the
site of infection and intensive care support with fluids, nutrition, mechanical ventilation
and continuous artificial kidney support. This persistently high death rate continues to
stimulate the development of new approaches to the treatment of septic shock.

Much clinical and molecular biology research suggests that these patients die because of an
uncontrolled immune system's response to infection. This response involves the production of
several substances (so called "humoral mediators"), which enter the blood stream and affect
the patient's organs ability to function and the patient's ability to kill germs. These
substances may potentially be removed by new artificial filters similar to those currently
used during continuous hemofiltration (the type of artificial kidney support used in
intensive care).

Recent investigations by ourselves and others, however, have made the following findings:

1. Standard filters currently used in intensive care are ineffective in removing large
amounts of these "humoral mediators" because the holes in the filter are too small to
allow all of them to pass through

2. The standard filters currently used in intensive care are also ineffective in removing
large amounts of these "humoral mediators" because the standard filtration flow through
the membrane is less than 100 ml/min

3. When the filtration flow through the membrane is increased to above 100ml/min, patients
require a lesser dose of drugs to support their blood pressure which is an indirect sign
that the filters are clearing some of the "humoral mediators"

4. Even when the blood flow through standard filters is increased to above 100ml/min, there
is still not optimal clearing of "humoral mediators" It is possible, however, that,
using a different filter membrane with bigger holes in it, would make it easier to clear
the blood of these "humoral mediators". It is thought that this would be noticeable
clinically in the amount of drugs required to support blood pressure.

A filter that has these bigger holes is now available. It is made of the same material as the
standard filters that are currently used in the intensive care unit, only the holes have been
made bigger to allow these "humoral mediators" to be removed from the blood. This polyamide
filter is made of synthetic semipermeable material. This material is highly compatible with
human blood. This modified polyamide filter is made of exactly the same compatible material
but the holes in the material are slightly larger through a minor modification of the
manufacturing process.

This larger hole filter has now been used in preliminary studies in humans and has been found
to reduce the blood levels of some "humoral mediators". Laboratory studies conducted by
ourselves showed that this new filter can achieve the highest reported clearance of some of
the "humoral mediators" with minimal effect on useful proteins in blood such as albumin
during hemodialysis. This loss is very small and unlikely to contribute to any detectable
clinical changes.

We, therefore, now propose to study the effect of using new large hole filters with
hemodialysis in patients with severe infections and acute kidney failure.

We wish to compare the effect of this new therapy to that of standard filters. The new
therapy will be considered to be effective if it lowers the amount of drugs used to support
blood pressure and if it lowers the blood levels of some "humoral mediators" more than
standard therapy. We will also monitor blood levels of important components of blood such as
albumin and electrolytes in each group.

This is a pilot study involving only 10 patients who will each receive 4 hours of the
standard therapy and 4 hours of the new therapy. Which treatment the patient receives first
will be random (like the tossing of a coin). Blood samples will be taken at the start and
after 4 hours of each treatment. The waste product of dialysis called spent dialysate will
also be collected for the measurement of humoral mediators at the start and after 4 hours of
each treatment. The changes in blood pressure and drugs used to support it will be recorded
hourly. As patients involved in the study would normally receive hemofiltration because of
their kidney failure, all the risks and benefits associated with the procedure would be
unchanged. The only risk to patients would come from exposure to a modified membrane and from
having two additional spoonfuls of blood taken.

If this new membrane were found to have a major effect on the blood level of "humoral
mediators" and on the patients' blood pressure, further studies would then be justified to
assess its clinical effects (time in ICU, time in hospital, time on ventilator, duration of
organ failure, etc).
Trial website
https://clinicaltrials.gov/ct2/show/NCT00333593
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Rinaldo Bellomo, MD, FRACP
Address 0 0
Austin Health
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00333593